CHRS Stock Summary and Trading Ideas (Coherus Oncology | NASDAQ:CHRS)

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

What symbol and exchange does Coherus Oncology shares trade?

Coherus Oncology trades on the NASDAQ stock market under the symbol CHRS.

What is Coherus Oncology stock price doing today?

As of February 11, 2026, CHRS stock price declined to $2.04 with 879,235 million shares trading.

What is Coherus Oncology's Beta?

CHRS has a beta of 0.95, meaning it tends to be less sensitive to market movements. CHRS has a correlation of 0.03 to the broad based SPY ETF.

How much is Coherus Oncology worth?

CHRS has a market cap of $246.58 million. This is considered a Small Cap stock.

How much money does Coherus Oncology make?

Last quarter Coherus Oncology reported $12 million in Revenue and -$.33 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.01.

What is the highest and lowest price Coherus Oncology traded in the last 3 year period?

In the last 3 years, CHRS traded as high as $8.65 and as low as $.66.

What are the top ETFs holding Coherus Oncology?

The top ETF exchange traded funds that CHRS belongs to (by Net Assets): IWM, VTI, VXF, IWN, SCHA.

Is Coherus Oncology (CHRS) a good investment?

CHRS has outperformed the market in the last year with a return of +74.4%, while the SPY ETF gained +15.6%. In the last 3 month period, CHRS beat the market returning +61.9%, while SPY returned +1.8%. However, in the most recent 2 weeks CHRS has underperformed the stock market by returning -18.7%, while SPY returned -0.5%.

What are the support and resistance levels for Coherus Oncology (CHRS)?

CHRS support price is $1.97 and resistance is $2.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CHRS shares will trade within this expected range on the day.